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Double plant homeodomain finger 2 (DPF2) is a highly evolution-
arily conserved member of the d4 protein family that is ubiqui-
tously expressed in human tissues and was recently shown to
inhibit the myeloid differentiation of hematopoietic stem/progen-
itor and acute myelogenous leukemia cells. Here, we present the
crystal structure of the tandem plant homeodomain finger domain
of human DPF2 at 1.6-Å resolution. We show that DPF2 interacts
with the acetylated tails of both histones 3 and 4 via bipartite
binding pockets on the DPF2 surface. Blocking these interactions
through targeted mutagenesis of DPF2 abolishes its recruitment to
target chromatin regions as well as its ability to prevent myeloid
differentiation in vivo. Our findings suggest that the histone bind-
ing of DPF2 plays an important regulatory role in the transcrip-
tional program that drives myeloid differentiation.
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The founding member of the d4 family of proteins, d4, zinc,and double plant homeodomain (PHD) finger 2 (DPF2, also
known as requiem/REQ or ubi-d4), was initially discovered as a
factor required for apoptosis in myeloid cells (1). d4 proteins,
which in humans also include DPF1 and DPF3b, are character-
ized by an N-terminal requiem domain, a central C2H2-type zinc
finger domain, and a C-terminal tandem PHD finger (2). PHD
fingers, which contain two zinc finger motifs, are notable for
their ability to read a diverse number of posttranslational
modifications, including unmodified, methylated, or acetylated
lysines, as well as unmodified arginines (3). Besides such pu-
tative binding capabilities of the DPF2 tandem PHD finger
domain, relatively little is known about the regulation and
function of DPF2 or its remaining individual domains. Previous
studies have shown that DPF2 bridges SWI/SNF components
and RelB/p52 to affect noncanonical NF-κB signaling (4), acts
as a globin switching factor (5), and is a target for Staufen-
1–mediated mRNA decay (5). Notably, DPF2 is expressed ubiq-
uitously in human tissues compared with DPF1 and DPF3b (6, 7).
DPF2, along with DPF1 and DPF3b, has been implicated in a
range of human cancers, including cervical cancer and acute mye-
logenous leukemia (AML) (8–13). Runt-related transcription factor
1 (RUNX1, also known as AML1) functions as an AML tumor-
suppressor gene, which is frequently inactivated through somatic
mutations and chromosomal translocations, including t(8;21), which
produces the AML1–ETO fusion protein (14). Recent work has
shown that recruitment of DPF2 into a RUNX1-containing re-
pressor complex inhibits the expression of RUNX1 target genes,
including the myeloid-specific microRNA miR-223, and inhibits
myeloid differentiation (8). DPF2 recruitment appears to depend
on arginine methylation events of RUNX1, as it is blocked by
mutation of RUNX1 Arg223 or chemical inhibition of the
type I arginine methyltransferase PRMT4. Knockdown of either
DPF2 or PRMT4 increases miR-223 gene expression and myeloid
differentiation. These findings suggest a model in which DPF2 and
RUNX1 form a methylation-dependent repressive complex in
AML, although it remains unclear whether the two proteins bind
each other directly or act concertedly as part of a larger complex.
Here, we present the crystal structure of the human DPF2
tandem PHD finger domain at a 1.6-Å resolution. We demon-
strate that the DPF2 tandem PHD finger domain binds acetylated
H3 and H4 histone tails, identify the primary determinants of
histone recognition, and confirm these interactions in vivo. We
further show that a histone-binding–deficient DPF2 mutant fails
to inhibit myeloid differentiation of human hematopoietic stem/
progenitor cells (HSPCs), demonstrating the importance of this
interaction for DPF2 function. Finally, we map the protein–pro-
tein interaction network of DPF2 in leukemia cells and find that
DPF2 and RUNX1 share many common interaction partners,
including components of the SWI/SNF chromatin-remodeling
complex. Together, these data support the conclusion that the
histone binding of DPF2 plays an important regulatory role in
myeloid differentiation.
Results
Crystallization and Structure Determination of Human DPF2. Based
on secondary structure prediction and sequence conservation
analyses, we designed a series of N-terminal truncation con-
structs of Homo sapiens DPF2 for recombinant protein expres-
sion in Escherichia coli (Table S1). We identified a fragment
corresponding to the tandem PHD finger domain, encompassing
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residues 270–391, hereafter referred to as DPF2PHD. DPF2PHD
was prone to oxidation as observed by mass spectrometry and
required immediate use in any experiments following purifica-
tion. Crystals of DPF2PHD were obtained in the tetragonal space
group I422 and diffracted to 1.6-Å resolution. The structure was
solved by single-wavelength anomalous dispersion using anom-
alous X-ray diffraction data, taking advantage of the four en-
dogenously bound Zn2+ ions per DPF2PHD molecule. The final
model contains residues 270–386, has excellent stereochemical
properties, and was refined to Rfree and Rwork values of 18.7%
and 14.6%, respectively. For further details of the data collection
and refinement statistics, see Table S2.
Crystal Structure of DPF2PHD Reveals a Characteristic Tandem PHD
Finger Domain. DPF2PHD contains two individual PHD finger
motifs, the first comprised of residues 270–329 and the second of
residues 330–386 (hereafter referred to as PHD1 and PHD2,
respectively) (Fig. 1A). Each PHD finger contains the canonical
architecture first described for the Williams syndrome tran-
scription factor (Fig. 1 and Fig. S1) (15). This includes a two-
stranded antiparallel β-sheet (β1–2 in PHD1 and β3–4 in PHD2)
and two zinc atoms coordinated by a His-Cys3 motif followed by
a Cys4 motif in a cross-brace topology (Cys273, Cys276, His303,
Cys306 and Cys295, Cys298, Cys324, Cys327 for PHD1; and
Cys330, Cys333, His353, Cys356 and Cys345, Cys348, Cys371,
Cys374 for PHD2) (Fig. S1A). PHD1 and PHD2 adopt a similar
conformation, with a RMSD of ∼1.9 Å over 45 Cα atoms (Fig.
S1B). The two PHD fingers mainly differ in the presence of an
additional short α-helix in PHD1 (αB, residues 311–319),
resulting in three flanking helices in PHD1 (αA, αB, and αC)
compared with two in PHD2 (αD and αE) (Fig. 1B).
Evolutionary Conserved DPF2PHD Front Surface Binds Histones in a
Bipartite Manner. A multispecies sequence alignment shows
DPF2PHD to be highly evolutionary conserved from H. sapiens to
Nematostella vectensis, with ∼50% sequence identity among all
species tested (Fig. S2). Whereas the surface of DPF2PHD main-
tains the high level of conservation observed for the entire do-
main, the front surface appears to be the most invariant region of
the protein (Fig. 1D). This surface contains a large hydrophobic
patch on its N-terminal half and a large negatively charged patch
on its C-terminal half, corresponding to PHD1 and PHD2, re-
spectively (Fig. 1 C and E). Additionally, among human d4 family
members, DPF2PHD shows an even greater level of conservation,
with ∼80% sequence identity (Fig. S3A). Despite being closely
related in sequence, a structural comparison of the DPF3bPHD
solution NMR structure in complex with various histone peptides
and our DPF2PHD crystal structure uncovered a movement in the
relative position of the individual PHD domains, corresponding to
a rotation by ∼25° (Fig. 2A) (16). Because of the high sequence
identity between the two proteins, the absence of obvious differ-
ences in the PHD1–PHD2 interface, and the presence of a pre-
dicted hinge region between the two PHD finger domains, the
observed conformational changes appear to be a result of ligand
binding (17).
Fig. 1. Structure of the human DPF2 tandem PHD finger domain. (A) Do-
main structure. Light gray, predicted unstructured regions (U); blue, requiem
domain (REQUIEM); dark gray, C2H2 zinc finger domain (C2H2); yellow, PHD
finger 1 (PHD1); orange, PHD finger 2 (PHD2). The bar above the domain
structure marks the crystallized fragment. (B) Structure of the DPF2 tandem
PHD finger domain in ribbon representation, colored as in A. Zn2+ atoms are
depicted as red (PHD1) and gray (PHD2) spheres. (C) Surface representation
of DPF2PHD colored as in A (yellow, PHD1; orange, PHD2). (D) Surface rep-
resentation of DPF2PHD colored according to a multispecies sequence align-
ment (Fig. S2). (E) Surface representation of DPF2PHD colored according to
electrostatic potential. The electrostatic potential is plotted onto the surface
and colored in a gradient from −10 kBT/e (red) to +10 kBT/e (blue).
Fig. 2. Structural comparison of the DPF2 and DPF3b tandem PHD finger
domains. (A) A ribbon representation of DPF2PHD (Left, colored as in Fig. 1A),
DPF3bPHD•H3K14Ac (Center, colored in gray, PDB ID code 2KWJ) (16), and a
superposition of the two, based on alignment of PHD2s (Right). The hinge
between PHD1 and PHD2 is indicated by an arrow. (B) Surface representa-
tions of the DPF3bPHD•H3K14Ac (Upper, PDB ID code 2KWJ) and the
DPF3bPHD•H4K16Ac (Lower, PDB ID code 2KWN) solution NMR structures
(16). Boxes show a cartoon representation of the indicated binding sites
superposed with our DPF2PHD crystal structure. Residues constituting the
bipartite histone-recognition motif are shown in stick representation.
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These results led us to explore the possibility that DPF2PHD
binds histone tails, possibly with a preference for post-
translational modifications that differs from DPF3b. Indeed,
isothermal titration calorimetry (ITC) measurements revealed
that DPF2PHD binds H3 or H4 peptides with dissociation con-
stants (Kd) of ∼1 and ∼50 μM, respectively, but independent of
their acetylation status in physiological buffer conditions (Fig. 3
A–C, Table 1, and Fig. S4 A and B). As previously described for
DPF3bPHD and consistent with the high conservation of d4
family tandem PHD finger domains, DPF2PHD preferentially
binds to H3 histone peptides (Fig. 3 B and C and Table 1) (16).
To investigate whether histone tail binding to DPF2 is governed
by electrostatic interactions, we determined the dissociation
constants in reduced salt conditions. In line with the electrostatic
properties of the DPF2 peptide binding surface, we observed
substantially tighter binding to all histone peptides in low-salt
conditions (Table S3). In contrast to the histone tail interac-
tions, we were unable to detect DPF2PHD binding to mono-
methyl- and asymmetric dimethyl-arginine RUNX1 peptides,
even under no-salt conditions (Table 1 and Fig. S4C). These data
suggest that the previously described methylation-dependent
interaction between DPF2 and RUNX1 occurs indirectly (8).
Together, our results establish that histone tail binding con-
stitutes a common property shared among different members of
the d4 family.
Identification of Essential Residues for DPF2 Histone Tail Binding.
Despite extensive efforts, in all DPF2PHD crystals we obtained,
crystal packing was mediated by the same surface involved in his-
tone tail binding, thus interfering with the determination of the
complex structure. To identify individual DPF2 residues involved
in histone binding, we therefore modeled the DPF2PHD interac-
tions with H3K14Ac and H4K16Ac using the NMR structures of
DPF3bPHD in complex with histone peptides as references (16).
The resulting model suggests that histone peptides interact in a
bipartite fashion with two distinct binding sites on the highly con-
served front surface of DPF2 (Fig. 2B). The first binding site en-
gages the acetyl-lysine residue with a hydrophobic pocket on the
surface of PHD1, which is primarily composed of Phe275, Leu307,
and Trp322. The second binding site is located on the negatively
charged PHD2 surface and includes DPF2 residues Glu326 and
Asp346, which make electrostatic interactions with Lys4 and
Arg2 residues of the histone H3 tail, respectively.
Using the structural models of the DPF2PHD•H3K14Ac and
DPF2PHD•H4K16Ac complexes as guides, we attempted to identify
specific DPF2 residues critical for histone tail binding through
site-directed mutagenesis followed by ITC. Alanine mutation of
DPF2 residues Phe275 and Arg300 in the first binding site and
Asp346 in the second binding site, hereafter referred to
as DPF2MUT, dramatically reduced the interaction with histone
tail peptides to levels that were not measurable by ITC in
physiological buffer conditions (Fig. 3 B and C and Table 1). The
observed loss of histone tail binding was not a result of improper
DPF2MUT protein folding, as confirmed by circular dichroism
(CD) spectroscopy (Fig. S5).
Together, these results pinpoint essential binding pockets in
the DPF2PHD surface that directly mediate its interactions with
histone tails.
DPF2 Binds Acetylated Histones H3 and H4 in Vivo. We used our
structure-guided mutational analysis as a guide to validate the in-
teraction of DPF2 with H3 and H4 histones in vivo. First, we tested
the cellular localization of FLAG-tagged DPF2 and DPF2MUT and
confirmed that both proteins show identical localization patterns by
cell fractionation or immunofluorescence microscopy and are pre-
dominantly localized to the nucleus (Fig. 3 D and E, Table S4).
In line with our biochemical analysis, wild-type DPF2 but not
DPF2MUT is able to bind H3 or H4 in vivo (Fig. 3F). However, this
interaction was dependent on acetylation of H3 and H4, suggesting
that additional determinants modulate the DPF2–histone interac-
tion in an acetylation sensitive fashion in vivo. Together, these re-
sults demonstrate that DPF2 residues Phe275, Arg300, and
Asp346 within the tandem PHD finger domain are essential for its
recruitment to histones.
Repression of Myeloid Differentiation Is Dependent on DPF2
Chromatin Recruitment. Having previously shown that DPF2 is
recruited to the pre-miR-223 promoter region (8), we investigated
whether this recruitment is mediated by the interaction of DPF2
Fig. 3. DPF2 binds histone tails in vitro and in vivo. (A) Sequences and
modifications of histone-tail peptides used in biochemical interaction stud-
ies. (B) Representative ITC data for interactions between an acetylated
H3K14Ac (Left) and DPF2 wild-type (DPF2WT), and H3K14Ac and a DPF2 triple
mutant (DPF2MUT; F275A, R300A, and D346A) (Right) at 100 mM salt con-
centration. Upper parts of each box show raw data and Lower parts show
integrated heat changes corrected for heat from dilution. (C) Representative
ITC data for interactions between an acetylated H4K16Ac (Left) and DPF2WT,
and H4K16Ac, and DPF2MUT (Right) at 100 mM salt concentration. Upper
parts of each box show raw data and Lower parts show integrated heat
changes corrected for heat from dilution. (D) Immunofluorescence locali-
zation analysis of FLAG-DPF2. 293T cells were transfected with FLAG-DPF2 or
FLAG-DPF2MUT and costained for anti-FLAG and DAPI to visualize nuclei.
Upper and Lower panels represent different cells from the same experiment.
(Scale bars, 10 μm.) (E) Subcellular DPF2 localization analysis. Whole-cell ly-
sate (WCL), cytoplasmic (CY), nuclear (NU), and chromatin bound (CH) frac-
tions of FLAG-DPF2– or FLAG-DPF2MUT–transfected 293T cells were isolated
and resolved by SDS-PAGE and probed for antibodies against FLAG and
controls for each fraction. (F) In vivo analysis of the DPF2-histone interaction.
293T cells were transfected with FLAG-DPF2 or FLAG-DPF2MUT constructs
followed by a 24-h incubation with the histone deacetylase (HDAC) inhibitor
Vorinostat or DMSO. FLAG constructs were immunoprecipitated using anti-
FLAG magnetic beads and lysates were probed for total histone H3 and H4.
Input (10%) is shown in the Lower panel and probed with antibodies to total
H3, total H4, and FLAG.
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with histones. To reduce the influence of endogenous DPF2, we
overexpressed wild-type DPF2 and the histone-binding–deficient
mutant DPF2MUT in MOLM-13 cells, which have low endogenous
DPF2 levels compared with other AML cell lines (Fig. 4 A and
B). Next, we performed ChIP assays using an anti-DPF2 antibody
and primer pairs that amplify the RUNX1 binding site within the
pre-miR-223 promoter region. Whereas wild-type DPF2 is pri-
marily located at region 4 of the pre-miR-223 promoter region in
MOLM-13 cells (Fig. 4 C–E), DPF2MUT displayed substantially
reduced recruitment to this promoter region (P < 0.005), com-
parable to a non-DPF2 responsive promoter (Fig. 4D) (8). Con-
sistently, there was no significant difference between DPF2WT
and DPF2MUT at the nonresponsive promoter (P > 0.1) (Fig. 4D).
Next, we examined the effect of DPF2 chromatin recruitment on
the myeloid differentiation of human cord blood (CB) CD34+ cells
by using lentiviral expression of either wild-type DPF2 or DPF2MUT
(Fig. 4F). After 7 d in myeloid differentiation-promoting cultures,
the proportion of CD11b+ cells originating from wild-type DPF2-
overexpressing CD34+ cells was markedly reduced, from 87.5 to
44.1%, compared with control cells. In contrast, DPF2MUT over-
expression did not reduce the number of CD11b+ cells (Fig. 4 G
and H). Thus, DPF2 negatively regulates myeloid differentiation
and this activity is dependent on its histone binding ability.
To further understand how DPF2 regulates HSPC biology, we
performed RNA sequencing of the CD34+ CB cells transduced with
either DPF2 knockdown (KD) or scrambled control shRNAs (Fig.
S6A). Experiments were conducted in triplicate. We found
438 genes that were differentially expressed between the DPF2 KD
and the control shRNA transfected cells, of which 133 and 305 were
down- and up-regulated, respectively. Functional annotation of the
RNA sequencing results by gene-set enrichment analysis (GSEA)
using the Molecular Signature Database revealed that only a single
gene set, Negative Regulation of Transcription-DNA Dependent,
was enriched in DPF2 KD CD34+ cells. In contrast, three gene sets,
Mitosis, Cell Cycle Regulation, and M-Phase, were down-regulated
in the DPF2 KD CD34+ cells (Fig. S6 B and C). Additionally, we
carried out an independent classification of the enriched molecular
functions using the Gene Ontology Consortium (GO) database,
which identified regulation of transcription, RNA processing, and
cell-cycle regulation, consistent with the Molecular Signature Da-
tabase findings (Tables S5–S7).
Thus, DPF2 plays an active role in the regulation of the tran-
scriptional program alterations that are associated with myeloid
differentiation.
Common Binding Partners Bridge DPF2 and Methylated RUNX1. To
decipher the regulatory role of DPF2 in myeloid differentiation,
we analyzed its protein–protein interaction network, performing a
comprehensive immunoprecipitation and mass spectrometry
analysis of endogenous DPF2 from two different t(8;21) leukemia
cell lines, SKNO-1 and Kasumi-1. This analysis revealed that
DPF2 interacts with members of the SWI/SNF complex and sev-
eral other epigenetic regulatory protein assemblies (Fig. S7 and
Table S8). The interaction of endogenous DPF2 with the three
SWI/SNF components BAF155/SMARCC1, BAF179/SMARCC2,
and BAF53/ACTL6A, was confirmed by Western blot in
Kasumi-1 cells (Fig. 5A). Next, we tested whether the interaction
of DPF2 with the SWI/SNF complex members depends on the
histone-binding ability of DPF2PHD. Indeed, when FLAG-tagged
DPF2MUT was immunoprecipitated from 293T cells, we observed
a marked reduction in its interaction with these three SWI/SNF
components compared with wild-type DPF2 (Fig. 5B). Thus, the
histone-binding ability of DPF2PHD is required for the interaction
of DPF2 with the SWI/SNF chromatin-remodeling complex.
A comparison of previously determined RUNX1 interaction
partners that specifically interact with a dimethylated Arg223
RUNX1 peptide and the newly established DPF2 interaction net-
work identified 22 common interaction partners (Fig. 5C and Tables
S8 and S9). Notably, these interaction partners include five members
of the SWI/SNF complex. Although previous studies showed that
DPF2 interacts with RUNX1 in a methylation-dependent manner
(8), RUNX1 was not identified as a DPF2 interaction partner in our
immunoprecipitation/mass spectrometry experiments. However,
DPF2 coimmunoprecipitated with FLAG-tagged RUNX1 in HEL
cells and this interaction was dependent on the presence of the N-
terminal region of DPF2, which encompasses the requiem and
central C2H2 zinc finger domains (Fig. 5D). Together, these data
suggest that the DPF2–RUNX1 interaction is mediated by chro-
matin modification complexes.
Discussion
We have conducted a comprehensive biochemical, structural, and
functional analysis of the d4 family member DPF2, identifying its
important role in blocking myeloid differentiation. We determined
the crystal structure of the DPF2 tandem PHD finger domain and
demonstrated its binding to histone tails. The histone-binding
ability of DPF2 is essential for its in vivo regulatory role in the
myeloid differentiation of HSPCs, and for its recruitment to spe-
cific chromatin sites, including the pre-miR-223 promoter.
The recognition of histone acetylation and other epigenetic
modifications by reader domains, including PHD domains, is a
major mechanism of epigenetic regulation and a source of dysregulation
in hematopoietic malignancies. For example, chromosomal trans-
locations that fuse the NUP98 gene with genes that encode PHD
Table 1. Isothermal titratrion calorimetry measurements
Protein Peptide Kd (μM) ΔH (kcal/mol) ΔS (cal/mol/deg)
DPF2WT H3 1.0 ± 0.3 −6.2 ± 0.2 6.8
H3K14Ac 1.1 ± 0.4 −9.7 ± 0.2 −5.3
H4 30.2 ± 13.2 −6.3 ± 0.7 −0.2
H4K16Ac 50.4 ± 5.7 −9.1 ± 0.5 −10.5
DPF2MUT H3 Not measurable Not measurable Not measurable
H3K14Ac Not measurable Not measurable Not measurable
H4 Not measurable Not measurable Not measurable
H4K16Ac Not measurable Not measurable Not measurable
DPF3b* H3 2.3 ± 0.7 −4.4 ± 0.2 11.1
H3K14Ac 0.5 ± 0.1 −6.6 ± 0.1 6.7
H4 28.8 ± 7.8 −3.3 ± 0.4 9.7
H4K16Ac 46.9 ± 10.0 −4.6 ± 0.6 4.4
DPF2WT RUNX1R223Me Not measurable Not measurable Not measurable
RUNX1R223ADMA Not measurable Not measurable Not measurable
*Data reported in Zeng et al. (16).
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domain-containing proteins, such as JARID1A or PHF23, have
been identified in patients with AML (18–21). In both cases, the
PHD domains of JARID1A or PHF23, which function as methyl-
lysine recognition domains, are conserved in the fusion protein
and shown to be critical for Hox gene activation and leukemia
induction in vivo (22).
The tandem PHD domains of the MOZ and MORF histone
acetyltransferases represent another example of histone reader
domains that regulate hematopoiesis. The MOZ and MORF
PHD domains recognize acetylated, crotonylated, and butyrylated
H3K14, and acetylated H3K9 in vitro (23). Both acetyltransferase
genes are involved in chromosomal translocations in leukemia that
result in their fusion to CBP, EP300, or TIF2 (24–26).
Collectively, these studies indicate that loss of the normal
recognition of histone modifications can have widespread effects
on myeloid transcription and HSPC differentiation and self-
renewal. The findings also suggest that targeting oncogenic epi-
genetic readers, such as PHD domains, could be a therapeutic
strategy for treating myeloid malignancies. In one example of
such an approach, chemical inhibitors that target the bromodo-
main of the BET family member, BRD4, have shown efficacy in
treating mixed lineage leukemia gene-rearranged leukemia, as
well as multiple myeloma and acute lymphoblastic leukemia
(ALL) (27–29).
DPF2 is mutated in several human cancers including AML,
lymphoma, and ALL (30), with mutation hot spots occurring
within the N-terminal region as well as the PHD domains. Sev-
eral of these N-terminal residues are predicted to be sites of
posttranslational modifications, including multiple arginines that
represent potential targets of the arginine methyltransferase
enzymes PRMT1, PRMT4, and PRMT5 (31, 32). We, and oth-
ers, have shown that myeloid differentiation is regulated by
specific arginine methylation events, and PRMT4 modifies sev-
eral proteins in the larger DPF2 interactome, including RUNX1
and the SWI/SNF subunit BAF155 (8, 33). Thus, the recognition
of histone modifications by the PHD domains of DPF2 poten-
tially integrates multiple epigenetic inputs and likely enables the
targeting of DPF2 to specific chromatin sites.
Our data highlight the important role of DPF2 in AML;
DPF2 is a potential new therapeutic target that can possibly
trigger the myeloid differentiation or apoptosis of leukemia cells
(Fig. 6). Although DPF2 is ubiquitously expressed, we show that
Fig. 5. Protein–protein interaction network of DPF2. (A) Confirmation of
SWI/SNF interacting proteins identified by the mass spectrometry analysis
of proteins precipitated with endogenous DPF2. Whole-cell lysates from
Kasumi-1 cells were immunoprecipitated with DPF2-conjugated beads and
interacting proteins were analyzed by Western blot. (B) Confirmation of
SWI/SNF interacting proteins identified by the mass spectrometry analysis
using FLAG-DPF2 constructs. Wild-type FLAG-DPF2 (DPF2WT) and FLAG-
DPF2MUT proteins were immunopreciptated from 293T cells using anti-
FLAG magnetic beads and analyzed by Western blot. (C ) Overlapping
DPF2 and RUNX1 interaction partners. Comparison of mass spectrometry
analysis of the proteins interacting with endogenous DPF2 and proteins
interacting with the dimethyl-Arg223-RUNX1 peptide. DPF2 interacting
proteins are normalized to an IgG control and methyl-RUNX1 interacting
proteins are normalized to a nonmethylated peptide control. There were
22 protein interaction partners shared between the two datasets. (D) In
vivo analysis of the DPF2–RUNX1 interaction. Coimmunoprecipitation of
FLAG-RUNX1 with DPF2 and the isolated DPF2PHD domain. FLAG-
RUNX1 and DPF2 or DPF2PHD were overexpressed in HEL cells by lentiviral
transduction. Cells were lysed after 72 h, immunoprecipitated with anti-
FLAG magnetic beads, and analyzed by Western blot. Input is 10% of the
nuclear extract.
Fig. 4. DPF2 recruitment to histones inhibits myeloid differentiation.
(A) Expression of DPF2 in a panel of acute leukemia cell lines compared with
normal CD34+ CB cell control. DPF2 was detected with an anti-DPF2 antibody
at a concentration of 1:1,000 (sc-101943, Santa Cruz). (B) Overexpression of
DPF2 wild-type (DPF2WT) or DPF2 triple mutant (DPF2MUT; F275A, R300A, and
D346A) protein in MOLM-13 cells as assessed by Western blot analysis.
(C) Occupancy of the miR-223 promoter regions in MOLM-13 cells, over-
expressing DPF2WT or DPF2MUT protein. Blue and yellow bars represent re-
gions 4 and 5 of the miR-223 promoter region, respectively. Data represent
the mean ± SD from three independent experiments. (D) Occupancy of a
non-DPF2 responsive promoter (albumin) region in MOLM-13 cells, over-
expressing DPF2WT or DPF2MUT protein. Data represent the mean ± SD from
three independent experiments. (E) Schematic representation of the
miR-223 promoter region. Two black lines represent the RUNX1 binding site
in the miR-223 promoter region. (F) Overexpression of DPF2WT or DPF2MUT
protein in human CB CD34+ cells as assessed by Western blot analysis.
(G) DPF2MUT blocks the repressive effect of DPF2 on myeloid differentiation
of HSPCs. CD34+ cells expressing DPF2WT, DPF2MUT, or a vector control were
cultured in myeloid differentiation-promoting cytokines for 7 d. Myeloid
differentiation was determined by FACS analysis for expression of CD11b. A
representative experiment is shown. (H) Data represent the mean ± SD of
percent CD11b+ cells from three independent experiments. *P < 0.01 by
Student’s t test.
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it is overexpressed in AML cell lines, and in AML patient samples,
where it represents a poor prognosis indicator (Fig. S8). Over-
expression or mutation of DPF2 is expected to alter its histone-
binding properties. However, further work is needed to elucidate
the mechanism by which histone modifications modulate DPF2’s
role in controlling myeloid differentiation, especially in light of
studies implicating several histone acetyltransferases in hema-
topoietic differentiation and self-renewal. Nonetheless, the re-
sults presented here provide a solid foundation for further
studies aiming to trigger the differentiation of AML cells through
targeted manipulation of DPF2.
Methods
Details for X-ray diffraction data collection and structure refinement are
described in SI Methods and Table S2. Further details of molecular cloning,
protein expression, purification, crystallization, CD spectroscopy, ITC mea-
surements, cell culture, cell fractionation, mass spectrometry, immunofluo-
rescence microscopy, immunoprecipitation, generation of lentivirus,
immunoblot analysis, flow cytometry, RNA sequencing, and ChIP assays
are described in SI Methods and Tables S1 and S3–S9.
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Fig. 6. Model for the inhibitory role of DPF2 in myeloid differentiation.
Histone-binding of DPF2 along with PRMT4 mediated methylation of
RUNX1 residue Arg223 trigger the formation of a DPF2 containing repressive
complex that is recruited to the miR-223 promoter. The interaction between
DPF2 and methylated RUNX1 is either mediated by the DPF2 N-terminal
region or bridged by components of a larger complex, such as the SWI/SNF
chromatin remodeling complex. Formation of the repressive DPF2 containing
RUNX1 complex on the miR-223 promoter region results in the repression of
miR-223 transcription and a subsequent block of myeloid differentiation. As
hematopoietic stem cells differentiate, the reduction in PRMT4 expression
leads to disassembly and replacement of the repressive transcriptional
complex by an activating complex that up-regulates transcription of miR-
223, among other genes.
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